Histone demethylase LSD1 (lysine specific demethylase 1) inhibitor

An aryl and hydroxyl technology, which is applied in the field of histone lysine demethylase LSD1 inhibitors, can solve the problems that LSD2 cannot be found, proteins cannot form complexes, etc.

Active Publication Date: 2017-09-19
福建金乐医药科技有限公司
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

LSD2 is similar to LSD1. With the participation of FAD, it can specifically remove the monomethyl and dimethyl modifications of H3K4 in vitro. However, the difference between LSD2 and LSD1 in biolog

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Histone demethylase LSD1 (lysine specific demethylase 1) inhibitor
  • Histone demethylase LSD1 (lysine specific demethylase 1) inhibitor
  • Histone demethylase LSD1 (lysine specific demethylase 1) inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] The preparation of the derivative (compound-1) shown in embodiment 1 general formula (I)

[0082] 4-((R)-3-phenyl-4-(((R)-1-propylpyrrolin-2-yl)methylene)piperazin-1-yl)phenol (hereinafter referred to as compound 1) preparation

[0083]

[0084] Compound-1

[0085] This compound can be prepared by the following steps:

[0086]

[0087] 1.1 Preparation of (R)-2-(2-(benzyloxycarbonylamino)acetamido)-2-phenylacetic acid methyl ester (1-2)

[0088]

[0089] 2-Benzyloxycarbonylaminoacetic acid (1-1) (2.98 g) and R-2-amino-2-phenylacetic acid methyl ester hydrochloride (3.0 g, 14.3 mmol) were suspended in anhydrous dichloromethane (30 mL), HBTU (6.66 g) and DIEA (7.4 g, 57.4 mmol) were added. After the reaction mixture was stirred overnight at room temperature, water (10 mL) was added, and after separation, the organic phase was extracted twice with dichloromethane (10 mL×2), and the combined organic phase was washed once with saturated brine, washed with anhydro...

Embodiment 2

[0112] Example 2 Preparation of derivatives represented by general formula (I) (compound-2)

[0113] Preparation of (R)-4-(3-phenyl-4-(piperidin-4-ylmethylene)piperazin-1-yl)phenol (hereinafter collectively referred to as compound 2)

[0114]

[0115] Compound-2

[0116] This compound can be prepared by the following steps:

[0117]

[0118] 2.1 (R)-1-(4-(N-tert-butoxycarbonylpiperidinyl)methylene)-2-phenyl-4-(4-(tert-butyldimethylsilyloxy)phenyl) ) Preparation of piperazine (2-1)

[0119]

[0120] (R)-1-(4-(tert-Butyldimethylsilyloxy)phenyl)-3-phenylpiperazine (1-5) (100 mg) and 1-tert-butoxycarbonylpiperidine-4- Formaldehyde (69 mg) was obtained using the same experimental procedure as in step 1.5 to obtain (R)-1-(4-(N-tert-butoxycarbonylpiperidinyl)methylene)-2-phenyl-4-(4- (tert-butyldimethylsilyloxy)phenyl))piperazine (2-1) 130 mg. LC-MS (ESI): m / z (M+1) 566.4.

[0121] Phenyl-4-(piperidin-4-ylmethylene)piperazin-1-yl)phenol ( Compound 2 ) preparation

[...

Embodiment 3

[0125] The preparation of the derivative (compound-3) shown in embodiment 3 general formula (I)

[0126] Preparation of (S)-4-(4-(4-hydroxybenzyl)-3-phenylpiperazin-1-yl)phenol (hereinafter referred to as compound 3)

[0127]

[0128] Compound-3

[0129] This compound can be prepared by the following steps:

[0130]

[0131] 3.1 Preparation of (S)-2-(2-(benzyloxycarbonylamino)acetamido)-2-phenylacetic acid methyl ester (3-2)

[0132]

[0133]2-Benzyloxycarbonylaminoacetic acid (3-1) (2.98 g) and S-2-amino-2-phenylacetic acid methyl ester hydrochloride (3.0 g) were dissolved in anhydrous DMF (30 mL), and HBTU was added (6.66 g) and DIEA (7.4 g). After the reaction mixture was stirred overnight at room temperature, water (30 mL) and ethyl acetate (10 mL) were added, and after separation, the aqueous phase was extracted with ethyl acetate (10 mL X 3), and the combined organic phase was washed 3 times with brine , dried over anhydrous sodium sulfate, filtered and conc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a histone demethylase LSD1 (lysine specific demethylase 1) inhibitor. The invention relates to piperazine-containing compounds and pharmacologically acceptable salts thereof and use of the piperazine-containing compounds and pharmacologically acceptable salts thereof as the LSD1 inhibitor; the general structural formula of the piperazine-containing compounds is described in the description. The invention belongs to the field of pharmaceutical chemistry. An in-vitro LSD1 activity inhibition test proves that the piperazine-containing compounds implemented by the invention have an obvious inhibiting effect for LSD1 activity, thus being used as active ingredients for preparing LSD1 inhibitor medicines.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and in particular relates to a class of piperazine-containing compounds or pharmaceutically acceptable salts thereof and their application as histone lysine demethylase LSD1 inhibitors. Background technique [0002] Abnormal expression or regulation of epigenetic proteins can lead to many diseases including cancer. For example, many pathological changes in cancer cells involve abnormal expression or regulation of one or more epigenetic proteins. By interfering with and inhibiting the epigenetic proteins involved in the disease, the process of the disease can be inhibited or even reversed, so as to achieve the purpose of alleviating or curing the disease. Now there are several anti-cancer drugs targeting epigenetic proteins on the market in the world. Epigenetic modification generally refers to DNA methylation and modification of histones. Histone modifications include acetylation, methylation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D241/04C07D403/06A61K31/496A61K31/495A61P35/00C07B53/00
CPCC07B53/00C07B2200/07C07D241/04C07D403/06
Inventor 周中祥邢园园陈应忠邓承军张书祖邓洪癸李芳
Owner 福建金乐医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap